Amarin Corporation PLC (AMRN) Stock AnalysisAMRNStock AnalysisAmarin Corporation PLC

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Amarin Corporation PLC is not a strong buy at the moment. The current price is $13.97, which is above the analyst price target of $13, suggesting limited upside potential. Additionally, the RSI is at 42.93, indicating that the stock is nearing oversold territory but not yet in a strong buying position. The company has reported a significant year-over-year revenue decline of 42% in Q2 2026, which raises concerns about its future performance.

5 analysts cover AMRN: 5 rate it Buy, 0 Hold and 0 Sell.